ArticlePeerJ2026
One-year all-cause mortality and comorbidity predictors in 14,975 adults with PCR-confirmed COVID-19: a retrospective Turkish cohort study.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), produces outcomes ranging from mild illness to death. Although in-hospital prognostic factors are well described, long-term mortality data are scarce, particularly from middle-income countries with relatively young populations. We therefore quantified one-year all-cause mortality and identified independent predictors in a large Turkish cohort support follow-up planning and prevention for high-risk groups. Methods: We retrospectively included all adults (≥18 years) with polymerase chain reaction-confirmed SARS-CoV-2 infection who presented to Haydarpaşa Numune Training and Research Hospital between 1 March 2020 and 31 January 2021, covering the pre-vaccination period in Türkiye. Demographics, smoking status, and ICD-10 coded comorbidities were extracted from hospital's electronic medical record system and national electronic health database. Follow-up was complete: 98.9% had 365 days; the remaining 168 had 360-364 days and were administratively censored, with no losses to follow-up. Missing smoking data was imputed by multiple imputations with chained equations. One-year survival status was obtained from the death registry. Risk factors were examined by Cox proportional hazards models after verifying assumptions. Results: Among 14,975 patients (median age 40 years, interquartile range 28.5-52.2; 50.8% male), 357 deaths occurred within 365 days, giving one-year mortality of 2.4% (95% CI [2.1-2.6]%). Non-survivors were older (71.8 Conclusion: One-year mortality after COVID-19 in this relatively young Turkish population was low yet clinically meaningful. Persistent excess risk among older adults, men, and patients with cancer or major cardiometabolic disease supports structured post-acute surveillance, prioritized vaccination boosters, and aggressive management of underlying conditions. The inverse association with smoking is probably due to residual or unmeasured confounding and should not influence practice. These findings refine long-term risk stratification and can guide resource allocation as COVID-19 becomes an endemic threat external validation that incorporates vaccination status and viral variants is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.